Regeneron Pharmaceuticals (NASDAQ:REGN) Cut to Hold at Argus

Argus cut shares of Regeneron Pharmaceuticals (NASDAQ:REGN - Free Report) from a buy rating to a hold rating in a research report released on Monday morning, MarketBeat.com reports.

Several other equities research analysts also recently weighed in on REGN. Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Bank of America decreased their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research report on Thursday, April 17th. UBS Group cut their price target on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a report on Thursday, June 5th. Citigroup reduced their price objective on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a research note on Monday, June 2nd. Finally, Canaccord Genuity Group raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 22nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $822.58.

Regeneron Pharmaceuticals Trading Down 0.5%

NASDAQ REGN traded down $2.74 during trading hours on Monday, hitting $545.00. 456,413 shares of the company's stock were exchanged, compared to its average volume of 905,431. The firm has a market cap of $58.84 billion, a price-to-earnings ratio of 13.87, a PEG ratio of 2.01 and a beta of 0.33. The stock has a 50-day simple moving average of $551.63 and a 200 day simple moving average of $628.53. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 1-year low of $476.49 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The business's quarterly revenue was down 3.7% compared to the same quarter last year. During the same period last year, the business earned $9.55 EPS. On average, equities analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.65%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of REGN. Pinney & Scofield Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. grew its position in Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares during the period. Activest Wealth Management grew its position in Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 21 shares during the period. Costello Asset Management INC purchased a new stake in Regeneron Pharmaceuticals during the first quarter worth about $27,000. Finally, Saudi Central Bank bought a new stake in Regeneron Pharmaceuticals in the first quarter worth about $27,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.